Ebola (EBOV) is an enveloped, negative-sense RNA virus belonging to the family Filoviridae that causes hemorrhagic fever syndromes with high-mortality rates. To date, there are no licensed vaccines or therapeutics to control EBOV infection and prevent transmission. Consequently, the need to better understand the mechanisms that regulate virus transmission is critical to developing countermeasures. The EBOV VP40 matrix protein plays a central role in late stages of virion assembly and egress, and independent expression of VP40 leads to the production of virus-like particles (VLPs) by a mechanism that accurately mimics budding of live virus. VP40 late (L) budding domains mediate efficient virus-cell separation by recruiting host ESCRT and ESCRT-associated proteins to complete the membrane fission process. L-domains consist of core consensus amino acid motifs including PPxY, P(T/S)AP, and YPx (n) L/I, and EBOV VP40 contains overlapping PPxY and PTAP motifs whose interactions with Nedd4 and Tsg101, respectively, have been characterized extensively. Here, we present data demonstrating for the first time that EBOV VP40 possesses a third L-domain YPx (n) L/I consensus motif that interacts with the ESCRT-III protein Alix. We show that the YPx (n) L/I motif mapping to amino acids 18-26 of EBOV VP40 interacts with the Alix Bro1-V fragment, and that siRNA knockdown of endogenous Alix expression inhibits EBOV VP40 VLP egress. Furthermore, overexpression of Alix Bro1-V rescues VLP production of the budding deficient EBOV VP40 double PTAP/PPEY L-domain deletion mutant to wild-type levels. Together, these findings demonstrate that EBOV VP40 recruits host Alix via a YPx (n) L/I motif that can function as an alternative L-domain to promote virus egress.
Ebola virus (EBOV) and Marburg virus (MARV) are enveloped, negative-strand RNA viruses and members of the Filoviridae. These filoviruses cause severe hemorrhagic syndromes with high-mortality rates in humans and nonhuman primates [1, 2] and are categorized by guidelines of the Centers for Disease Control and Prevention and the National Institutes of Health (NIH) as BSL-4 agents. The current lack of approved vaccines or antiviral therapeutics for these pathogens is problematic because outbreaks and new strains continue to emerge, as exemplified by the ongoing Ebola (Zaire) outbreak in West Africa. Thus, there remains a vital need for the development of effective and safe therapeutics and vaccines against these emerging, high-priority pathogens.
It is well established that the filovirus VP40 matrix protein plays a key role in driving virion assembly and budding. Indeed, independent expression of EBOV VP40 (eVP40) or MARV VP40 (mVP40) leads to the production and budding of virus-like particles (VLPs) by a mechanism that accurately mimics that of live virus [3] [4] [5] [6] [7] . Using this VLP system, we and others have established that efficient filovirus budding is dependent on the subversion of specific host proteins associated with the cellular ESCRT machinery (eg, Tsg101 and Nedd4) by viral Late (L) domains within eVP40 as well as mVP40 and mNP proteins [3, 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Viral L-domains consist of conserved consensus amino acid motifs such as PPxY, P(T/S)AP, YPx (n) L/I, or FPIV (x = any amino acid; for review, see [6, 8, 22, 23] ) within matrix proteins of many RNA viruses. This conservation of structure suggests that L domains are generally required for efficient virus-cell separation [22, 23] . The 3 best characterized L-domain/host interactions that contribute to budding of many RNA viruses include the: (i) PTAP-Tsg101 interaction, (ii) PPxY-Nedd4 interaction, and (iii) YPx (n) L/I-Alix interaction [22, 23] .
Alix is an ESCRT associated protein that facilitates virus egress by bridging ESCRT-I and ESCRT-III components via interactions with viral YPx (n) L/I L-domain motifs [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Alix consists of 3 major domains named Bro1 (aa 1-366), V (aa 367-701), and PRD ( proline-rich domain, aa 702-868) and each mediates interactions with a multitude of cellular and viral proteins (for review, see [43] ). A number of interactions mediated by these domains of Alix are important for retrovirus budding. For example, the Alix V domain binds to the viral YPx (n) L/I L-domain motif within human immunodeficiency virus type 1 (HIV-1) and EIAV Gag, the Bro1 domain interacts with the ESCRT-III protein CHMP4 and membrane lipid LBPA to promote membrane bending, and the PRD domain interacts with the ESCRT-I protein Tsg101 and calcium binding protein ALG-2 [43] .
To date, there have been no reports suggesting a role for Alix in filovirus budding; however, a role for Alix in EBOV budding could account for the fact that an eVP40 mutant lacking both PTAP and PPEY L-domains (eVP40-ΔPT/PY) can still bud as a VLP, albeit at levels lower than those of VP40 wild type (WT). Similarly, recombinant EBOV containing mutations in both PTAP and PPEY L-domains is viable in cell culture, although budding of this double mutant is also reduced compared to WT EBOV [11] . These results indicate that additional host proteins/pathways can play a complementary, overlapping, or redundant role in EBOV budding. Interestingly, we have identified a YPx (n) L/I-type motif between amino acids 18-26 of eVP40, which is similar to an HIV-1 Gag motif that mediates interactions with Alix and can rescue budding of HIV-1 Gag PTAP deletion mutants [24, 26, 35] . In addition to EBOV VP40, the YPx (n) L/I-type motif is also present in SUDV and BDBV VP40 proteins but not in those of RESTV and TAFV.
Here we demonstrate for the first time that endogenous Alix, through its interactions with the eVP40 YPx (n) L/I-type motif, contributes to efficient egress of eVP40 VLPs. We also demonstrate that the Alix Bro1-V region physically interacts with eVP40-ΔPT/PY and that Bro1-V rescues deficient budding of eVP40-ΔPT/PY. Finally, we demonstrate that the Bro1-V/ eVP40-ΔPT/PY interaction is dependent on the YPx (n) L/Itype motif spanning N-terminal amino acids 18-26 of eVP40. These findings have important implications for our complete understanding of the complex virus-host interactions required for efficient egress and spread of EBOV.
MATERIALS AND METHODS
Cell Lines, Plasmids, and Reagents HEK293T and COS-1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (100 U/mL)/streptomycin (100 µg/mL) at 37°C in a humidified 5% CO 2 incubator. The pCAGGS based plasmids expressing eVP40-WT and eVP40-ΔPT/PY have been described elsewhere [5, 10] . The pCAGGSbased plasmid expressing eVP40-ΔPT/PY-A2 was generated by mutating 18 YP 19 amino acids in the eVP40-ΔPT/PY background to AA using standard polymerase chain reaction (PCR) and cloning techniques. pHM6-based plasmids expressing Alix-WT, Bro1, Bro1-V, and V-PRD were kindly provided by F. Bouamr (NIH/NIAID) and have been described previously [26] .
VLP Budding Assay
Filovirus VLP budding assays using HEK293T cells have been described elsewhere [5, 10, [44] [45] [46] . Proteins in VLPs and cell lysates were detected by SDS-PAGE and Western blot using polyclonal rabbit anti-VP40 antibody for eVP40-WT, eVP40-ΔPT/PY, and eVP40-ΔPT/PY-A2; mouse anti-HA antibody for HA-tagged Alix-WT, Bro1, Bro1-V, V-PRD proteins; and anti-actin antibody (Sigma).
siRNA Transfection
Human Alix-specific or random siRNAs were purchased from Dharmacon. HEK293 T cells in collagen-coated 6-well plates were transfected twice with either random or Alix siRNAs at a final concentration of 200 nM using Lipofectamine (Invitrogen) at 2-day intervals. The final transfection included both siRNAs and 0.5 µg of eVP40 expression plasmid. VLPs and cell lysates were harvested at 24 hours following the last transfection as described above. eVP40 protein levels in VLPs and eVP40, and Alix levels in cell extracts, were analyzed by Western blotting and quantified using NIH Image-J software.
IP/Western Analysis
Cos-1 cells were transfected with the indicated plasmids using Lipofectamine reagent (Invitrogen) and the protocol of the supplier. Cells were harvested and lysed in nondenaturing buffer (20 mM Tris-HCl [ pH = 8.0], 137 mM NaCl, 1.0% Nonidet P-40 [NP-40], 2.0 mM EDTA, and 10% glycerol) at 24 hours post-transfection. Cell lysates were clarified for 10 minutes and then incubated with anti-eVP40 or normal rabbit immunoglobuling G (IgG; Cell Signaling) overnight at 4°C. rProtein A/G agarose beads (Invitrogen) were added to the samples, which were incubated with agitation for 2 hours at 4°C. The beads were washed 5× in nondenaturing lysis buffer, suspended in loading buffer with boiling, and then fractionated by SDS-PAGE. HA-tagged Alix-WT or Bro1-V were detected in samples by Western blot using anti-HA antiserum.
RESULTS

Alix Regulates eVP40 VLP Budding
We evaluated the role of endogenous Alix in eVP40 VLP egress by suppressing its expression in HEK293T cells. Alix suppression (>90%, Figure 1A , lane 3) did not affect cellular eVP40 protein levels; however, eVP40 VLP budding was reduced in Alixsuppressed cells by approximately 4-fold ( Figure 1A and 1B) relative to random siRNA controls ( Figure 1A and 1B), indicating a role for Alix in efficient eVP40 VLP egress from HEK293T cells.
Alix Rescues eVP40 VLP Budding
The Bro1, V, and PRD domains of Alix play critical roles in retrovirus-host interactions required to drive efficient budding [25, 27, 32, 33, 39, 41, 47, 48] . Indeed, overexpression of Alix rescues budding of PTAP L-domain mutants of HIV-1 Gag, which cannot interact with host Tsg101 [26, 35] . We first sought to determine whether overexpression of full-length WT or the Bro1-V fragment would affect budding of either eVP40-WT or eVP40-ΔPT/PY, a budding defective PTAP/PPEY double L-domain deletion mutant of eVP40 [9, 10] . Briefly, eVP40-WT budding from HEK293T cells ( We used an identical approach to determine whether other Alix domains (Bro1 and V-PRD) could enhance budding of eVP40-ΔPT/PY VLP egress (Figure 3 ). Once again, we foundthat expression of Bro1-V enhanced eVP40-ΔPT/PY VLP release by approximately 4-fold ( Figure 3 , compare lanes 2 and 4); however, expression of the Alix Bro1 or V-PRD domains had little to no effect on eVP40-ΔPT/PY VLP egress (Figure 3 , compare lanes 2, 3, and 5). Together, these data demonstrate that the Bro1-V fragment rescues budding of the double L-domain deletion mutant of eVP40 most efficiently and suggest that Alix functions as an auxiliary target for eVP40 engagement of the ESCRT pathway in the absence of functional VP40 PTAP and PPEY L-domains.
eVP40-ΔPT/PY Interacts With Alix Bro1-V
Because the Alix Bro1-V fragment rescues eVP40-ΔPT/PY VLP budding most efficiently and colocalized with eVP40-ΔPT/PY in confocal microscope images (data not shown), we asked whether the mechanism of rescue involved a direct interaction between these two proteins. To test this, eVP40-ΔPT/PY was expressed in COS-1 cells with vector alone or Bro1-V, and after 24 hours we quantified Bro1-V levels in eVP40-specific immuneprecipitates ( Figure 4A ). Importantly, Alix Bro1-V was detected in eVP40-ΔPT/PY precipitates (lane 4), but was not detected in precipitates produced with control antiserum ( Figure 4A , lane 3) or in precipitates from cells that expressed control vector ( Figure 4A, lanes 1 and 2) . We also demonstrate that expression levels of eVP40-ΔPT/PY, Bro1-V, and actin in appropriate samples are equivalent ( Figure 4B ). These results demonstrate that Bro1-V interacts with eVP40-ΔPT/PY, and it should be noted that Bro1-V was detected in eVP40-ΔPT/PY VLPs (Han and Harty, data not shown). Figure 5A ). We asked whether this putative L domain is required for the interaction we observed between Bro1-V and eVP40-ΔPT/PY and also the rescue of eVP40-ΔPT/PY VLP budding. To test this, we first mutated the YPx (6) I sequence to AAx (6) I in the eVP40-ΔPT/PY background to generate eVP40-ΔPT/PY-A2 ( Figure 5A ). Either eVP40-ΔPT/PY or eVP40-ΔPT/PY-A2 were expressed in HEK293T cells with either empty vector or Bro1-V ( Figure 5B ). Once again, we observed an enhancement in eVP40-ΔPT/PY VLP budding in the presence of Bro1-V vs vector control ( Figure 5B , VLPs, lanes 1 and 2). In contrast, we did not observe any enhancement in budding of eVP40-ΔPT/PY-A2 VLPs in the presence of Bro1-V compared to vector control ( Figure 5B, VLPs, lanes 3 and 4) . It should also be noted that basal levels of budding of eVP40-ΔPT/PY-A2 VLPs in the presence of vector alone ( Figure 5B , VLPs, lane 3) were lower than those of eVP40-ΔPT/PY VLPs ( Figure 5B , VLPs, lane 1), further suggesting that the YPx (6) I may function as an alternative eVP40 L-domain motif. We also demonstrate that expression levels of eVP40-ΔPT/PY, eVP40-ΔPT/PY-A2, Bro1-V, and actin are equivalent in appropriate samples ( Figure 5B) .
If, as our data suggest, the YPx (6) L/I motif in eVP40 represents a third viable L-domain motif, then we would predict that eVP40-ΔPT/PY, but not eVP40-ΔPT/PY-A2, should interact with Alix Bro1-V. To test this, eVP40-ΔPT/PY or eVP40-ΔPT/PY-A2 were expressed in COS-1 cells together with Bro1-V (or vector control) for 24 hours ( Figure 6A ).
Although each of these proteins exhibited comparable levels of expression ( Figure 6B ), Bro1-V was detected in eVP40-ΔPT/PY but not eVP40-ΔPT/PY-A2 immune-precipitates ( Figure 6A , compare lanes 4 and 6), Moreover, Bro1-V was not detected in vector (lane 2) or serum control immune-precipitates (lanes 1, 3, and 5). Together, these data suggest that the YPx (6) L/I motif mediates the interaction between VP40 and Bro1-V and establishes the YPx (6) L/I motif of eVP40 as a third functional 
Alix F676 is Required for Rescue of eVP40-ΔPT/PY VLP Budding
Residue F676 within the Bro1-V region of Alix plays a critical role in the interaction between Alix and YPX (n) L/I L-domain motifs of EIAV p9 and HIV-1 p6 Gag proteins [24] . Indeed, a F676D mutation in Alix reduced its ability to bind to the HIV-1 p6 Gag L-domain and prevented Alix mediated rescue of budding of an HIV-1 Gag PTAP deletion mutant [24, 31, 33, 49] . Thus, we sought to determine whether the F676D mutation likewise prevented rescue of eVP40-ΔPT/PY VLP budding. Briefly, eVP40-ΔPT/PY was expressed in HEK293T cells with WT Bro1-V or F676D Bro1-V and VLPs in supernatants were quantified 24 hours post-transfection (Figure 7 ). Cells contained equivalent amounts of eVP40-ΔPT/PY and Bro1-V, and eVP40-ΔPT/PY VLP budding was rescued (>6-fold increase compared to control) by WT (Figure 7 , VLPs, lane 2) but not F676D Bro1-V (Figure 7, VLPs, lane 3) . These data suggest that the mechanism of Bro1-V rescue involves Bro1-V F676 recognition of and binding to the YPx (6) I motif of eVP40-ΔPT/PY.
DISCUSSION
Host ESCRT protein Alix has a well-documented role in budding of retroviruses such as HIV-1 and EIAV [25, 33, 34, 38, 41, 43, 50] , and Alix has also been implicated in egress of other RNA viruses [47, [51] [52] [53] [54] . In this report, we present evidence for the first time showing that Alix has a role in budding of EBOV particles and have identified the structural domain of Alix that mediates its interaction with eVP40 required for budding. The V domain of Alix is critical for interactions with the YPx (n) L/I L-domain of HIV-1 and EIAV Gag [24, 25, 31, 33, 55] , and overexpression of Alix rescues budding of PTAP and/or PPxY L-domain deletion mutants of HIV-1 and EIAV Gag to WT levels [26, 28, 39, 41, 56] . For HIV-1, the PTAP-Tsg101 interaction is thought to be the predominant relevant interaction for recruiting ESCRT components, while the retroviral YPx (n) L/I dependent interaction with Alix is thought to function as an alternate mechanism by which the virus can recruit ESCRT components to facilitate budding [38, 41, 42, 57] .
Our results establish that expression of full-length Alix supports efficient egress of eVP40 VLPs, and specifically that the Bro1-V fragment of Alix is sufficient to rescue budding of a double PTAP/PPEY mutant of eVP40 to levels approaching those of eVP40-WT. Importantly, the Bro1-V rescue of eVP40-ΔPT/PY VLP budding involves a direct protein-protein interaction between the Alix V domain and the YPx (6) I motif at the N-terminus of eVP40. Moreover, a single F676D mutation within the Bro1-V domain, which is a residue required for its interactions with the HIV-1 p6 Gag YPx (n) L/I L-domain, abolished the ability of Bro1-V to rescue budding of eVP40-ΔPT/PY VLPs, as did a mutation that changed YPx (6) I to AAx (6) I within eVP40-ΔPT/PY.
Although expression of WT Alix enhances eVP40-ΔPT/PY VLP budding by approximately 2-3 fold, the Bro1-V fragment enhances eVP40-ΔPT/PY VLP budding by up to approximately 7-fold. This enhanced rescue by the shorter Bro1-V fragment may reflect a structural difference between the proteins. Indeed, intramolecular interactions are believed to lock Alix in a folded conformation [25, 58, 59] , which is maintained by interactions between the PRD region and Bro1-V. Thus, in the absence of the PRD region, the Bro1-V fragment may adopt a more open conformation that facilitates its interaction with the YPx (6) I motif of eVP40-ΔPT/PY to promote more efficient budding. Additional studies will be required to fully elucidate the mechanisms that regulate Alix activation and facilitate its interaction with eVP40 to promote budding.
An important and intriguing unanswered question is why many enveloped RNA viruses like EBOV have redundant L-domain motifs. One possibility is that the requirement for each viral L-domain reflects cell specific differences in the expression levels of their interacting host protein(s). The EBOV VP40 PTAP/PPEY L-domains and their recruitment of host Tsg101 and Nedd4 are thought to be the primary driving force for EBOV budding, whereas the recruitment of Alix via the eVP40 YPx (6) I motif likely serves as a secondary or alternate mechanism for EBOV egress. It should be noted that the YPx (n)-L/I-type motif is not conserved in RESTV and TAFV VP40 proteins, and perhaps this lack of conservation among the VP40 proteins reflects its role as an alternative L-domain motif.
In summary, we have identified and characterized a previously unrecognized third L-domain motif, YPx (6) I at aa 18-26 in EBOV VP40, which allows EBOV VP40 to interact with the host ESCRT protein Alix. The eVP40-Alix interaction can rescue a block in VLP formation that results from mutations in previously recognized eVP40 L-domain motifs and expands our current understanding of the role of ESCRT proteins in eVP40-mediated VLP formation. This new domain we have identified that mediates VP40-Alix interactions may represent a novel therapeutic target for control of EBOV infection. While these studies provide important new insight into the mechanisms of EBOV egress and host interactions, and while Alix may not be the primary ESCRT protein involved in budding, a better understanding of the interaction between Alix and EBOV VP40 may nonetheless pave the way for development of small molecule inhibitors of this virus-host interaction, that can be combined with antiviral therapeutics we have identified recently that target the PTAP-Tsg101 and PPxY-Nedd4 interactions [45, 46] . Indeed, drugs that target this YPx (6) I motif, if combined with PTAP and PPxY L-domain inhibitors, may prove to be more effective and less toxic than single L-domain inhibitors. The importance of identifying new targets and treatment modalities for this increasingly global public health challenge is highlighted by the extent of the current outbreak in West Africa and potential future outbreaks.
Notes
